Monkeypox vaccines: Marketed and Under Development
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
Monkeypox vaccines: Marketed and Under Development
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Monkeypox vaccines: Marketed and Under Development.
Monkeypox virus belongs to the genus Orthopoxvirus, the same genus of viruses as the variola virus that causes smallpox.
Because of the similarity of the two viruses, the smallpox vaccine is cross-protected against monkeypox .
Studies have shown that the smallpox vaccine is at least 85% effective in preventing monkeypox.
So far, there are two approved smallpox vaccines in the United States, developed by Acambis and Bavarian Nordic.
Among them, the smallpox vaccine Jynneos developed by Bavarian Nordic was approved by the US FDA in 2018 for the prevention of smallpox and monkeypox infection in high-risk adults over 18 years old.
This is the only non-replicating smallpox vaccine approved by the FDA and the only monkeypox vaccine approved in the world.
In addition, there is also an oral drug Tecovirimat for monkeypox virus approved, which is a broad-spectrum envelope protein inhibitor developed by Siga Technologies, showing good resistance to all orthopoxviruses Viral activity, including smallpox virus, monkeypox virus, etc.
In 2010, Tecovirimat was granted orphan drug designation by the FDA for the treatment of poxvirus infection, and was approved for marketing in 2018 for the treatment of smallpox in adults and children weighing at least 13kg under the trade name Tpoxx.
In January 2022, the EMA approved Tecovirimat for the treatment of smallpox, monkeypox, and cowpox.
Moderna responds quickly to deploy the development of mRNA vaccine
At the same time, Moderna , the world’s leading mRNA vaccine research and development company, announced that it will use its mRNA vaccine research and development platform to develop monkeypox mRNA vaccines.
At the end of 2019, the COVID-19 epidemic broke out. In early January 2020, Chinese scholars took the lead in sequencing and publishing the first new coronavirus genome sequence.
After the sequence was announced, Moderna started the research and development of new coronavirus mRNA the next day, developed a candidate mRNA vaccine in only 42 days, and completed the phase 3 clinical trial by the end of 2020, obtaining FDA emergency use authorization.
This has also allowed the world to witness the speed, flexibility and effectiveness of mRNA platforms.
Since then, Moderna company Stéphane Bancel said that Moderna has invested heavily in digitization, robotics and machine learning, and the next outbreak of a new outbreak can halve the time to develop a new vaccine to just 20 days.
Stéphane Bancel
Monkeypox vaccines: Marketed and Under Development
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
